Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 1
2(40.0%)
Phase 2
2(40.0%)
Phase 3
1(20.0%)
5Total
Phase 1(2)
Phase 2(2)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT07036185Phase 1Not Yet Recruiting

A Clinical Trail of KJ015 in Patients With HER2-Expressing Solid Tumors

Role: lead

NCT07025408Phase 2Recruiting

Phase II Clinical Trial of KJ101in the Treatment of Deep II Degree Burns

Role: lead

NCT06607016Phase 2Active Not Recruiting

A Clinical Trial With KJ103 in Anti-GBM Disease

Role: lead

NCT06604546Phase 3Completed

Hyaluronidase Assisted Subcutaneous Infusion

Role: lead

NCT05274659Phase 1Completed

A Study to Evaluate the Safety and Tolerability of KJ103 in Healthy Adults

Role: lead

All 5 trials loaded